Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Holtzman

Showing results (441-450 of 742) with videos related to

Pageof 75
Sort By:
Life Science Alliance|August 10, 2023
Parenchymal border macrophages regulate tau pathology and tau-mediated neurodegenerationAntoine Drieu, Siling Du, Michal Kipnis, et al.
Annals of Neurology|May 1, 2016
Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluidYo-El S Ju, Mary Beth Finn, Courtney L Sutphen, et al.
Neurosurgery|August 30, 2016
Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein α, and L1 Cell Adhesion MoleculeDiego M Morales, Shawgi A Silver, Clinton D Morgan, et al.
Neurology|January 14, 2011
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer diseaseC M Roe, A M Fagan, M M Williams, et al.
The American Journal of Pathology|August 28, 2004
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic miceMarcin Sadowski, Joanna Pankiewicz, Henrieta Scholtzova, et al.
The American Journal of Pathology|October 7, 2004
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosisAnne M Fagan, Erin Christopher, Jennie W Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2014
Proteopathic tau seeding predicts tauopathy in vivoBrandon B Holmes, Jennifer L Furman, Thomas E Mahan, et al.
JAMA Neurology|August 21, 2013
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivityLiang Wang, Matthew R Brier, Abraham Z Snyder, et al.
The Lancet. Neurology|September 10, 2013
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort studyStephanie Jb Vos, Chengjie Xiong, Pieter Jelle Visser, et al.
Annals of Clinical and Translational Neurology|August 23, 2016
Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathyErik S Musiek, David D Xiong, Tirth Patel, et al.
Pageof 75

Showing results (441-450 of 742) with videos related to

Sort By:
Pageof 75
Life Science Alliance|August 10, 2023
Parenchymal border macrophages regulate tau pathology and tau-mediated neurodegenerationAntoine Drieu, Siling Du, Michal Kipnis, et al.
Annals of Neurology|May 1, 2016
Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluidYo-El S Ju, Mary Beth Finn, Courtney L Sutphen, et al.
Neurosurgery|August 30, 2016
Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein α, and L1 Cell Adhesion MoleculeDiego M Morales, Shawgi A Silver, Clinton D Morgan, et al.
Neurology|January 14, 2011
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer diseaseC M Roe, A M Fagan, M M Williams, et al.
The American Journal of Pathology|August 28, 2004
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic miceMarcin Sadowski, Joanna Pankiewicz, Henrieta Scholtzova, et al.
The American Journal of Pathology|October 7, 2004
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosisAnne M Fagan, Erin Christopher, Jennie W Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2014
Proteopathic tau seeding predicts tauopathy in vivoBrandon B Holmes, Jennifer L Furman, Thomas E Mahan, et al.
JAMA Neurology|August 21, 2013
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivityLiang Wang, Matthew R Brier, Abraham Z Snyder, et al.
The Lancet. Neurology|September 10, 2013
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort studyStephanie Jb Vos, Chengjie Xiong, Pieter Jelle Visser, et al.
Annals of Clinical and Translational Neurology|August 23, 2016
Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathyErik S Musiek, David D Xiong, Tirth Patel, et al.
Pageof 75